Health ❯ Healthcare

Adverse Effects

Treatment-Emergent Adverse Effects Treatment-Related Adverse Effects Drug Safety Cytokine Release Syndrome Medication Side Effects Treatment-Related Adverse Events Vaccine Safety Vaccine Side Effects Myocarditis Safety Profiles Clinical Safety Pancreatitis Vaccine Adverse Event Reporting System Side Effects Treatment-related Adverse Effects Gastrointestinal Events Toxicity Profiles Chemotherapy Drug Toxicity Treatment Emergent Adverse Events Medication Errors Gastrointestinal Issues Safety Data Treatment-Related Events Drug Safety Profiles Toxicity Levels Clinical Research Blood Clots Overdose Symptoms Hypoglycemia Vaccine Reactions Emergency Room Visits Immune-Related Adverse Events Medication Safety Mental Health Gastrointestinal Side Effects Treatment Tolerability Irritation Vaccine-Related Myocarditis

NEJM Study Identifies Viral Protein and Antibody Mutation Behind Rare Vaccine‑Linked Clots

The work traces the ultrarare syndrome to molecular mimicry between a viral protein and PF4.

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Early Cilta-Cel Use Linked to Better Outcomes in Relapsed/Refractory Myeloma, ASH 2025 Data Show

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

Pliant’s PLN-101095 With Keytruda Shows Early Responses in PD-1–Refractory Solid Tumors

FDA Approves Durvalumab Added to Perioperative FLOT for Resectable Gastric and GEJ Cancer

FDA Approves Perioperative Keytruda–Padcev for Cisplatin‑Ineligible Muscle‑Invasive Bladder Cancer

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

Pluvicto Added to Standard Care Extends rPFS in PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

EU Regulators Back Libtayo as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC